HGF/c-Met Cancer Research Results

HGF/c-Met, met proto-oncogene (hepatocyte growth factor receptor): Click to Expand ⟱
Source: CGL-Driver Genes
Type: Oncogene
Hepatocyte growth factor (HGF) and its high-affinity receptor, mesenchymal epithelial transition factor (c-Met), are closely related to the onset, progression, and metastasis of multiple tumors. The HGF/c-Met axis is involved in cell proliferation, movement, differentiation, invasion, angiogenesis, and apoptosis by activating multiple downstream signaling pathways.
HGF (Hepatocyte Growth Factor) and its receptor c-Met play significant roles in various biological processes, including cell growth, motility, and differentiation. Their involvement in cancer has been extensively studied, as the HGF/c-Met signaling pathway is often dysregulated in many types of tumors
: The HGF/c-Met pathway can promote tumor cell proliferation and survival. When HGF binds to c-Met, it activates several downstream signaling pathways, including the PI3K/Akt and MAPK pathways, which are crucial for cell survival and growth.
c-Met is associated with increased invasive and metastatic potential of cancer cells. The activation of this pathway can enhance the motility of cancer cells, allowing them to invade surrounding tissues and spread to distant sites.
Tumors that overexpress c-Met may evade the effects of treatment, leading to poor patient outcomes.
Scientific Papers found: Click to Expand⟱
680- EGCG,    Cancer preventive and therapeutic effects of EGCG, the major polyphenol in green tea
- Review, NA, NA
NF-kB↓, STAT3↓, PI3K↓, HGF/c-Met↓, Akt↓, ERK↓, MAPK↓, AR↓, Casp↑, Ki-67↓, PARP↑, Bcl-2↓, BAX↑, PCNA↓, p27↑, P21↑,
3201- EGCG,    Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential
- Review, NA, NA
*AntiCan↑, *cardioP↑, *neuroP↑, *BioAv↝, *BioAv↓, *BioAv↓, *Dose↝, *Half-Life↝, *BioAv↑, *BBB↑, *hepatoP↓, *other↓, *Inflam↓, *NF-kB↓, *AP-1↓, *iNOS↓, *COX2↓, *ROS↓, *RNS↓, *IL8↓, *JAK↓, *PDGFR-BB↓, *IGF-1R↓, *MMP2↓, *P53↓, *NRF2↑, *TNF-α↓, *IL6↓, *E2Fs↑, *SOD1↑, *SOD2↑, Casp3↑, Cyt‑c↑, PARP↑, DNMTs↓, Telomerase↓, Hif1a↓, MMPs↓, BAX↑, Bak↑, Bcl-2↓, Bcl-xL↓, P53↑, PTEN↑, TumCP↓, MAPK↓, HGF/c-Met↓, TIMP1↑, HDAC↓, MMP9↓, uPA↓, GlutMet↓, ChemoSen↑, chemoP↑,
2919- LT,    Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
- Review, Var, NA
RadioS↑, ChemoSen↑, chemoP↑, *lipid-P↓, *Catalase↑, *SOD↑, *GPx↑, *GSTs↑, *GSH↑, *TNF-α↓, *IL1β↓, *Casp3↓, *IL10↑, NRF2↓, HO-1↓, NQO1↓, GSH↓, MET↓, p‑MET↓, p‑Akt↓, HGF/c-Met↓, NF-kB↓, Bcl-2↓, SOD2↓, Casp8↑, Casp3↑, PARP↑, MAPK↓, NLRP3↓, ASC↓, Casp1↓, IL6↓, IKKα↓, p‑p65↓, p‑p38↑, MMP2↓, ICAM-1↓, EGFR↑, p‑PI3K↓, E-cadherin↓, ZO-1↑, N-cadherin↓, CLDN1↓, β-catenin/ZEB1↓, Snail↓, Vim↑, ITGB1↓, FAK↓, p‑Src↓, Rac1↓, Cdc42↓, Rho↓, PCNA↓, Tyro3↓, AXL↓, CEA↓, NSE↓, SOD↓, Catalase↓, GPx↓, GSR↓, GSTs↓, GSH↓, VitE↓, VitC↓, CYP1A1↓, cFos↑, AR↓, AIF↑, p‑STAT6↓, p‑MDM2↓, NOTCH1↓, VEGF↓, H3↓, H4↓, HDAC↓, SIRT1↓, ROS↑, DR5↑, Cyt‑c↑, p‑JNK↑, PTEN↓, mTOR↓, CD34↓, FasL↑, Fas↑, XIAP↓, p‑eIF2α↑, CHOP↑, LC3II↑, PD-1↓, STAT3↓, IL2↑, EMT↓, cachexia↓, BioAv↑, *Half-Life↝, *eff↑,
1200- LT,    Inhibition of Fatty Acid Synthase by Luteolin Post-Transcriptionally Downregulates c-Met Expression Independent of Proteosomal/Lysosomal Degradation
- in-vitro, Pca, DU145
FASN↓, cMET↓, HGF/c-Met↓,
3930- PTS,    A Review of Pterostilbene Antioxidant Activity and Disease Modification
- Review, Var, NA - Review, adrenal, NA - Review, Stroke, NA
*BioAv↑, *antiOx↑, *neuroP↑, *Inflam↓, *ROS↓, *H2O2↓, *GSH↑, *GPx↑, *GSR↑, *SOD↑, TumCG↓, PTEN↑, HGF/c-Met↓, PI3K↓, Akt↓, NF-kB↓, TumMeta↓, MMP2↓, MMP9↓, Ki-67↓, Casp3↑, MMP↓, H2O2↑, ROS↑, ChemoSen↑, *cardioP↑, *CDK2↓, *CDK4↓, *cycE/CCNE↓, *cycD1/CCND1↓, *RB1↓, *PCNA↓, *CREB↑, *GABA↑, *memory↑, *IGF-1↑, *ERK↑, TIMP1↑, BAX↑, Cyt‑c↑, Diablo↑, SOD2↑,

Showing Research Papers: 1 to 5 of 5

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↓, 1,   CYP1A1↓, 1,   GPx↓, 1,   GSH↓, 2,   GSR↓, 1,   GSTs↓, 1,   H2O2↑, 1,   HO-1↓, 1,   NQO1↓, 1,   NRF2↓, 1,   ROS↑, 2,   SOD↓, 1,   SOD2↓, 1,   SOD2↑, 1,   VitC↓, 1,   VitE↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 1,   MMP↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

FASN↓, 1,   GlutMet↓, 1,   SIRT1↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 2,   p‑Akt↓, 1,   Bak↑, 1,   BAX↑, 3,   Bcl-2↓, 3,   Bcl-xL↓, 1,   Casp↑, 1,   Casp1↓, 1,   Casp3↑, 3,   Casp8↑, 1,   Cyt‑c↑, 3,   Diablo↑, 1,   DR5↑, 1,   Fas↑, 1,   FasL↑, 1,   HGF/c-Met↓, 5,   p‑JNK↑, 1,   MAPK↓, 3,   p‑MDM2↓, 1,   p27↑, 1,   p‑p38↑, 1,   Telomerase↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

H3↓, 1,   H4↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP↑, 1,   p‑eIF2α↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

LC3II↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNMTs↓, 1,   P53↑, 1,   PARP↑, 3,   PCNA↓, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

P21↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD34↓, 1,   cFos↑, 1,   cMET↓, 1,   EMT↓, 1,   ERK↓, 1,   HDAC↓, 2,   mTOR↓, 1,   NOTCH1↓, 1,   PI3K↓, 2,   p‑PI3K↓, 1,   PTEN↓, 1,   PTEN↑, 2,   p‑Src↓, 1,   STAT3↓, 2,   p‑STAT6↓, 1,   TumCG↓, 1,  

Migration(tgid=13) ⓘ

AXL↓, 1,   Cdc42↓, 1,   CEA↓, 1,   CLDN1↓, 1,   E-cadherin↓, 1,   FAK↓, 1,   ITGB1↓, 1,   Ki-67↓, 2,   MET↓, 1,   p‑MET↓, 1,   MMP2↓, 2,   MMP9↓, 2,   MMPs↓, 1,   N-cadherin↓, 1,   Rac1↓, 1,   Rho↓, 1,   Snail↓, 1,   TIMP1↑, 2,   TumCP↓, 1,   TumMeta↓, 1,   Tyro3↓, 1,   uPA↓, 1,   Vim↑, 1,   ZO-1↑, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

EGFR↑, 1,   Hif1a↓, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

ASC↓, 1,   ICAM-1↓, 1,   IKKα↓, 1,   IL2↑, 1,   IL6↓, 1,   NF-kB↓, 3,   p‑p65↓, 1,   PD-1↓, 1,  

Protein Aggregation(tgid=19) ⓘ

NLRP3↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   ChemoSen↑, 3,   RadioS↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 2,   CEA↓, 1,   EGFR↑, 1,   IL6↓, 1,   Ki-67↓, 2,   NSE↓, 1,  

Functional Outcomes(tgid=23) ⓘ

cachexia↓, 1,   chemoP↑, 2,  
Total Targets: 119

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Catalase↑, 1,   GPx↑, 2,   GSH↑, 2,   GSR↑, 1,   GSTs↑, 1,   H2O2↓, 1,   lipid-P↓, 1,   NRF2↑, 1,   RNS↓, 1,   ROS↓, 2,   SOD↑, 2,   SOD1↑, 1,   SOD2↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

CREB↑, 1,  

Cell Death(tgid=5) ⓘ

Casp3↓, 1,   iNOS↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

P53↓, 1,   PCNA↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 1,   CDK4↓, 1,   cycD1/CCND1↓, 1,   cycE/CCNE↓, 1,   E2Fs↑, 1,   RB1↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↑, 1,   IGF-1↑, 1,   IGF-1R↓, 1,  

Migration(tgid=13) ⓘ

AP-1↓, 1,   MMP2↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

PDGFR-BB↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 1,   IL10↑, 1,   IL1β↓, 1,   IL6↓, 1,   IL8↓, 1,   Inflam↓, 2,   JAK↓, 1,   NF-kB↓, 1,   TNF-α↓, 2,  

Synaptic & Neurotransmission(tgid=18) ⓘ

GABA↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv↑, 2,   BioAv↝, 1,   Dose↝, 1,   eff↑, 1,   Half-Life↝, 2,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   cardioP↑, 2,   hepatoP↓, 1,   memory↑, 1,   neuroP↑, 2,  
Total Targets: 55

Scientific Paper Hit Count for: HGF/c-Met, met proto-oncogene (hepatocyte growth factor receptor)
2 EGCG (Epigallocatechin Gallate)
2 Luteolin
1 Pterostilbene
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:186  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page